News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InViragen Presents Safety and Immune Response Data from a Phase 1 Study of its Two-Dose Dengue Vaccine, DENVax


12/7/2011 7:14:20 AM

FORT COLLINS, Colo.--(BUSINESS WIRE)--Inviragen, Inc. presented results of the Phase 1 clinical trial of DENVax conducted in Colombia at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting today. In this randomized, placebo-controlled study of 96 healthy adults, DENVax was safe and well tolerated and induced significant neutralizing antibody responses to all four dengue virus subtypes. The most frequent adverse events reported were transient local injection site reactions.

Read at BioSpace.com


comments powered by Disqus
InViragen
 
 
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES